1231I and 1251I decay to emit highly radiotoxic Auger electrons, whose effective range, in terms of DNA damage, is a few nanometres (Martin et al, 1981) . In order to kill cells, these radionuclides must be incorporated into DNA (Kassis et al, 1987a) or be closely associated with it (Schwartz et al, 1996) . The thymidine analogue IUdR, labelled with radioiodine, has great potential as a radiotherapeutic agent that is capable of selectively targeting dividing cells. This cycle-specific treatment strategy is especially attractive for the elimination of malignant glioma cells because, when administered intracranially, IUdR should be toxic to the tumour but have no adverse effect on normal, quiescent tissue of the central nervous system (Kassis et al, 1990) .
Several in vitro studies have demonstrated the exquisite toxicity of 123I-and l251-iodinated IUdR to dividing cells (Hofer et al, 1975; Makrigiorgos et al, 1989; Schneiderman and Schneiderman, 1996) , and the effectiveness of locoregional administration of this agent has been shown in rodent models of gliosarcoma (Kassis, 1994) , meningeal carcinoma and ovarian ascites (Baranowska-Kortylewicz et al, 1991) . Recently, the incorporation of IUdR in a range of human tumours has been reported (Daghighian et al, 1996; Macapinlac et al, 1996; Mariani et al, 1996a and b) .
A well-recognized limitation of treatment with IUdR labelled with Auger electron-emitting radionuclides is the existence of a subpopulation of malignant cells that is not in the DNA synthetic phase of the cell cycle during the time of exposure to IUdR. Cells that fail to incorporate the IUdR into DNA will not be significantly exposed to the highly localized energy deposition of Auger electrons. Possible means of overcoming this limitation include the use of prolonged or repeated exposures, and the use of other treatment modalities in combination with Auger electron therapy. One potential complementary therapeutic agent is the beta emitter ['311 ]IUdR. Although less cytotoxic to the targeted proliferating cells than [1231] IUdR or [1251] IUdR (Hofer and Hugues, 1971; Chan et al, 1976) , the relatively long range of beta electrons results in the irradiation of neighbouring non-proliferating cells by the cross-fire or bystander effect (Humm, 1986; Wheldon and O'Donoghue, 1990 (Sutherland, 1988 
MATERIALS AND METHODS

Synthesis of radiolabelled lUdR
Radioiodinated (no-carrier-added) IUdR was prepared using the trialklytin derivative 5-(tributylstannyl)-2'-deoxyuridine. This precursor was readily synthesized from IUdR by a palladiumcatalysed substitution of the iodine for a tributyltin moiety essentially as described by Baranowska-Kortylewicz et al (1994) .
To 50 jg of 5-(tributylstannyl)-2'-deoxyuridine was added 155-178 jil of glacial acetic acid, 7.4 MBq of Na'25I, 230 MBq of Na'231 or 74 MBq of Nal3lI (Amersham International) and 20 jl of peracetic acid. This reaction mixture was incubated at room temperature for 5 min before injecting the total volume on to a semipreparative high performance liquid chromatography (HPLC) column. The 6-mi fraction containing the radiolabelled IUdR was collected and evaporated to dryness in vacuo. The IUdR was reconstituted in saline and sterilized by 0.22-gm filtration.
Cell culture UVW glioma cells, a subline derived from a human grade IV glioblastoma, were obtained from the Medical Oncology Department, CRC Beatson Laboratories, Glasgow, UK. They were cultured in Eagle's minimum essential medium (MEM) (Gibco BRL), supplemented with 10% (v/v) fetal calf serum (Gibco BRL), fungizone (2 jg ml-'), penicillin/streptomycin (100 lIU mn-l) and 200 mm glutamine. Cells were cultured as monolayers and as spheroids, as described by Kwok and Twentyman (1987) .
For monolayer culture, cells were plated in 20 ml of culture medium into 75-cm2 tissue culture flasks (Nunc, Denmark). The contents of the flasks were equlibrated with 5% carbon dioxide/ 95% air and were maintained at 37°C. All cells were tested for mycoplasma infection at 4-weekly intervals. The cultures were consistently shown to be uncontaminated.
Cultures of spheroids were initiated by inoculating 106 cells into a bacteriological Petri dish containing 15 ml of medium. After two days of incubation in 95% air / 5% carbon dioxide at 37°C, cell aggregates of approximately 100-jim diameter were selected and transferred to six-well plates (35 mm diameter) (Coming, New York) coated with 1% (w/v) agar, containing 4 ml of medium per well. Each well contained several aggregates, which subsequently grew as tumour spheroids.
Spheroid growth rates were measured to provide a basis for the selection of incubation times for radioactive IUdR labelling. They were evaluated by measuring two perpendicular diameters, using an inverted phase-contrast microscope connected to an image analyser. The spheroid volume-doubling time, determined from the initial exponential part of the growth curve, was 52 h.
Clonogenic assay
We determined the effect of radioiodinated IUdR upon the clonogenicity of UVW cell cultures treated in the exponential growth phase, in the plateau growth phase and growing as multicellular spheroids.
Aliquots consisting of 104 exponentially growing monolayer cells were seeded into multiwell plates (Coming, New York) containing 1 ml of complete MEM and incubated at 37°C with 5% carbon dioxide for 2 days. The medium was then removed and replaced with 1 ml of medium containing a range of concentra-
Controls contained equimolar non-radiolabelled IUdR or medium in place of radioiodinated reagents. Cell cultures in the plateau growth phase were established as described by Freshney et al (1980) and treated similarly. The cultures were incubated at 37°C with 5% carbon dioxide for 44 h (one doubling time for exponentially growing cells). The radioactive medium was removed, and the cells were washed with phosphate-buffered saline (PBS) until no further soluble radioactivity could be eluted. They were then trypsinized, serially diluted and seeded into 25-cm2 tissue culture flasks in triplicate. The number of cells seeded yielded 30-260 colonies after 10 days. A low-density feeder layer, comprising 104 heavily irradiated homologous cells (50-Gy single-dose irradiation), was added to each flask. This procedure was shown in preliminary experiments to enhance plating efficiency.
British Joumal of Cancer (1998) The spheroids were washed several times in culture medium until no further soluble radioactivity could be eluted. They were then treated with 0.5 ml of PBS containing 0.25% (v/v) trypsin and 1 mm EDTA for 10 min at 370C. After the addition of 0.5 ml of medium to neutralize the trypsin, the spheroids were mechanically disaggregated. Microscopic examination confirmed that the cell preparations were free of clumps. Seeding was performed as described above.
The ability of single cells to form colonies of 50 or more cells was considered to indicate clonogenic survival. Cell colonies, which formed after 9-11 days, were stained with 10% (v/v) Carbol Fuchsin (Ziehl-Neelsen, London) and air dried before counting. The mean surviving fraction was determined by dividing the number of colonies that grew after exposure to the radioactive compound by the number of colonies grown from control cultures exposed to medium alone. All experiments were performed in triplicate.
Flow cytometry
Uptake of IUdR was determined in cells in the exponential and the plateau phases of growth and in spheroids of 100-to 200-,um diameter. IUdR (Sigma, Poole, Dorset) was dissolved in medium to prepare a 100 jim solution, which was sterilized by filtration through 0. Non-radioactive IUdR at a concentration of 1.2 nm, which is equivalent to the maximum molar concentration of radiolabelled IUdR used in this study, was found to have no effect on cell survival as determined by the clonogenic assay. In addition, incubation of UVW monolayer cells in Na'251 or Na'31I at a concentration of 100 kBq ml-did not result in any measurable change in survival.
UVW monolayer cells in plateau phase Figure 2 shows the surviving fraction of monolayer cells in plateau phase after incubation with ['251 al, 1997) . In this study, we have assessed the relative efficacies of three radioiodoconjugates of deoxyuridine: two ultra-short range Auger electron emitters (1251 and 1231I) and one long-range beta emitter (13'I). We have expressed the results of the toxicity studies in terms of the initial concentration of radioactivity in the culture medium, rather than the number of radioactive decays per cell from DNAincorporated IUdR. It is clear from previous autoradiographic studies of IUdR incorporation (Neshasteh-Riz et al, 1997) that the quantity of incorporated radioactivity is highly variable from cell to cell in spheroid culture, in contrast to the more uniform uptake in exponentially growing monolayers. Hence, a representative value for the number of decays per cell cannot be specified for spheroids. However, to correct for the different rates of physical decay of the three radionuclides during the incubation period, and to estimate the relative number of decays per cell for a given rate of incorporation of IUdR, the formula derived by Makrigiorgos et al (1989) may be used: cumulative number of decays per cell = kC0[l-(1+XT)e-XT]/X2, where k is a constant representing the rate of uptake of radioactivity into cells relative to the concentration in the medium, C0 is the initial concentration of the extracellular radioactivity, X is the physical decay constant for the radionuclide in question and T is the incubation period. This formula assumes that the rate of incorporation of IUdR is proportional to the extracellular concentration and does not vary with time over the incubation period. Table 4 shows the relative number of decays for the three radioisotopes according to this formula for incubation periods of 44 and 52h, given equal initial concentrations of radioactivity in the medium.
In exponentially growing UVW monolayers, incorporation of ['251]IUdR was directly proportional to extracellular concentration, which is consistent with the findings of other authors (Kassis et al, 1987b; Makrigiorgos et al, 1989) . All three agents yielded exponential survival curves with no evidence of a shoulder for [1251] IUdR and [1231]IUdR, which is also consistent with previous studies (Kassis et al, 1987b; Makrigiorgos et al, 1989; Schneiderman and Schneiderman, 1996) , although ['311 ]IUdR has been reported to produce a curve with a shoulder in other cell lines (Hofer and Hugues, 1971; Chan et al, 1976) . This may reflect differences in the efficacy of DNA repair mechanisms in different cell lines and under different experimental conditions.
The initial concentration of the extracellular radioactivity required to achieve a given level of cell kill was approximately four times greater for 1231 than for 1251. However, the cumulative number of radioactive decays per cell for DNA-incorporated IUdR, as estimated by applying the decay correction factor in Table 4 , was approximately equal for the two Auger electron emitters. In Chinese hamster V79 lung fibroblasts, Makrigiorgos et al (1989) observed a twofold difference in cytotoxic efficacy (on the basis of decays per cell) in favour of [1251] IUdR for the same two radioiodinated drugs. It is again possible that the different result in the present study is related to differences in the cell lines, incubation periods and other experimental variables. The radioactive concentration required to reduce cellular survival to 37% was eight times greater for '3'I than for 1251 in exponentially growing monolayers. This is comparable with the elevenfold difference in effectiveness for these agents previously reported in L 1210 lymphoid leukaemia cells (Hofer and Hugues, 1971) and Chinese hamster V79 lung fibroblasts (Chan et al, 1976) . The superiority of 1251 and 123I relative to 1311 for the treatment of rapidly proliferating single cells is believed to be due to the high linear energy transfer (LET) characteristics of Auger electrons relative to 3-particles.
No saturation was observed in the cytotoxicity of the three agents in rapidly proliferating monolayer cells, and it was possible to achieve a cell kill of greater than 90% by administration of a sufficiently high concentration of radiopharmaceutical. This is in agreement with the BrdU labelling index as determined by flow cytometry, which indicates that essentially all cells in these conditions are in cycle and capable of incorporating the agent during DNA synthesis. However, under more clinically realistic conditions of tumour cell growth, the situation is more complex: a proportion of cells may be out of cycle or not actively involved in DNA synthesis during the period of exposure to IUdR, and this would be expected to limit the efficacy of DNA-targeted Auger electron emitters. Our experimental study supports this prediction. (Table 4) , this is difficult to explain if it is assumed that all cells that incorporate a significant fraction of the available activity for either agent at the highest concentration are killed. Closer agreement was observed between the labelling index as measured by flow cytometry in spheroids and the proportion of cells killed by ['251 ]IUdR rather than by ['23I]IUdR, suggesting that some factor may be limiting the cytotoxic effect of the latter agent in this model.
In contrast to the Auger electron emitters, [1311]IUdR was progressively more toxic at increasing doses in the spheroid model. This is consistent with microdosimetric expectations; whereas most of the decay energy of '13I incorporated in monolayers is dissipated above and below the plane of the cells, beta radiation cross-fire is effective in cellular aggregates. The absorbed fraction of the decay energy of 1311 (0.11 g Gy MBq-' h-1), uniformly distribued in tissue spheres of 100-,um diameter, has been calculated to be approximately 10% (O'Donoghue et al, 1995) . If the average rate of uptake of IUdR by cells in spheroids were the same as in monolayers (Table 3) , and assuming a cellular density of 5 x 108 cells g-1, the cross-fire radiation dose to spheroids during incubation with [1311] IUdR at a concentration of lOOkBq ml-1 would be approximately 8 Gy. The true average rate of uptake would be substantially smaller in spheroids than in monolayers because of the presence of non-cycling and slowly cycling cells, and, because of the highly non-uniform distribution of radioactivity, the radiation dose to individual cells is likely to vary considerably. However, an absorbed dose in the range of 4-5 Gy is of the correct order of magnitude to account for the 17-14% surviving fraction of glioma cells (Raaphorst et al, 1989; Taghian et al, 1992) . The data are therefore consistent with the interpretation that, in addition to DNA-synthesizing cells, adjacent non-cycling cells absorb a cytotoxic dose of beta decay energy in this model.
It is possible that the maximal therapeutic benefit may be derived from the use of 'cocktails' of IUdR containing different radioisotopes, including both Auger electron emitters to kill cycling cells and the beta emitter 1311 to eliminate untargeted cells British Journal of Cancer (1998) 77(3), 385-390 by cross-fire. However, the optimum agent or combination of agents for targeted radiotherapy of gliomas in vivo depends on several factors in addition to those addressed in this study, including the uptake of radiopharmaceutical by critical normal organs as well as rates of deiodination and escape from the intracranial space to the circulation. The short half-life of 1231 would be an advantage in this respect. We are evaluating the effects of some of these variables in an in vivo glioma model system.
Recently, high-specific-activity 5-[21'At]astato-2'-deoxyuridine ([2t'At]AUdR) has been synthesized and has been shown, like IUdR, to be readily incorporated into cellular DNA. However, [2ttAt]AUdR may be 100 times more toxic to clonogenic cells in vitro than 125I or ['231]IUdR (Vaidyanathan et al, 1996) . 21'At emits high LET alpha particles whose range is equivalent to a few cell diameters. These characteristics suggest that [211At]AUdR could be superior to Auger electron emitters both in terms of tumour cell kill and homogeneity of dose distribution. However, the use of [2t'At]-astatinated radiopharmaceuticals presents formidable difficulties in relation to logistics and radiation protection. The present studies assist in the design of treatment strategies for DNAtargeted radiotherapy using radiopharmaceuticals that are more readily available at present for clinical use.
